-
Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, Romagnoli V, Cherubini B, Moscato G, Maina AM, Cavallone D, Bonino F, 2010: Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers[J]. Gastroenterology, 139, 483-490. doi: 10.1053/j.gastro.2010.04.052
-
Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan H, Wong GL, Sung JJ, 2007: Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response[J]. Clin Gastroenterol Hepatol, 5, 1462-1468. doi: 10.1016/j.cgh.2007.09.005
-
Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ, 2010: A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B[J]. Hepatology, 52, 1232-1241. doi: 10.1002/hep.23803
-
Chan HL, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW, 2011a: Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients[J]. Antivir Ther, 16, 1249-1257. doi: 10.3851/IMP1921
-
Chan HL, Wong GL, Tse CH, Chan HY, Wong VW, 2011b: Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients[J]. J Infect Dis, 204, 408-414. doi: 10.1093/infdis/jir283
-
Chen YC, Sheen IS, Chu CM, Liaw YF, 2002: Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection[J]. Gastroenterology, 123, 1084-1089. doi: 10.1053/gast.2002.36026
-
Chen, Yang, Su, Jun, Jen, You, Lu, Huang, Iloeje, REVEAL-HBV Study Group, 2006: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 295, 65-73. doi: 10.1001/jama.295.1.65
-
Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association, 2019: The Guidelines of Prevention and Treatment for Chronic Hepatitis B (2019 Version)[J]. Zhonghua Gan Zang Bing Za Zhi, 27, 938-961.
-
Chu CM, Liaw YF, 2007: Spontaneous relapse of hepatitis in inactive HBsAg carriers[J]. Hep Intl, 1, 311-315. doi: 10.1007/s12072-007-9002-9
-
Chu CJ, Hussain M, Lok AS, 2002: Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection[J]. Hepatology, 36, 1408-1415. doi: 10.1002/hep.1840360617
-
Cornberg M, Wong WS, Locarnini S, Brunetto M, Janssen HLA, Chan HL, 2017: The role of quantitative hepatitis B surface antigen revisited[J]. J Hepatol, 66, 398-411.
-
European Association for the Study of the Liver. European Association for the Study of the Liver. EASL 2017 (2017) Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67: 370–398
-
Giersch K, Lena A, Tassilo V, Maura D, Marc L, 2017: Serum HBV pgRNA as a clinical marker for cccDNA activity[J]. J Hepatol, 66, 460-462. doi: 10.1016/j.jhep.2016.09.028
-
Gill U, Micco L, Li L, Peppa D, Ushiro-Lumb I, Foster G, Maini M, Kennedy P, 2011: Pegylated interferon alpha modulates innate immunity in eag positive chronic hepatitis B and determines changes in HBSag quantification[J]. J Hepatol, 54, S32-.
-
Hadziyannis SJ, Papatheodoridis GV, 2006: Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment[J]. Semin Liver Dis, 26, 130-141. doi: 10.1055/s-2006-939751
-
Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF, 2002: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B[J]. Hepatology, 35, 1522-1527. doi: 10.1053/jhep.2002.33638
-
Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, Jiang J, Xie Q, Dou X, Sun Y, Li Y, Liu Y, Liu G, Mao D, Chi X, Tang H, Li X, Xie Y, Chen X, Jiang J, Zhao P, Hou J, Gao Z, Fan H, Ding J, Zhang D, Ren H, 2018: HBsAg Loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new Switch Study[J]. J Clin Transl Hepatol Mar, 28, 25-34.
-
Hui CK, Lau GK, 2006: Current issues and future directions in treatment[J]. Semin Liver Dis, 26, 192-197. doi: 10.1055/s-2006-939757
-
Koffas A, Dolman GE, Kennedy PT, 2018: Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians[J]. Clin Med (Lond), 18, 212-218.
-
Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, Boninsegna S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B, Facchetti F, Colombo M, PegBe Liver Study Group (2013) Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 62: 290–298
-
Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N, Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352: 2682–2695
-
Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY, Mao XN, Zou HH, Zhang WH, 2015: Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment[J]. Antimicrob Agents Chemother, 7, 4121-4128.
-
Li MH, Zhang L, Qu XJ, Lu Y, Shen G, Wu SL, Chang M, Liu RY, Hu LP, Li ZZ, Hua WH, Song SJ, Xie Y, 2017: Kinetics of hepatitis B surface antigen level in chronic hepatitis b patients who achieved hepatitis B surface antigen loss during pegylated interferon alpha-2a treatment[J]. Chin Med J (Engl), 130, 559-565. doi: 10.4103/0366-6999.200554
-
Li MH, Yi W, Zhang L, Lu Y, Lu HH, Shen G, Wu SL, Hao HX, Gao YJ, Chang M, Liu YR, Hu LP, Cao WH, Chen QQ, Li JN, Wan G, Xie Y, 2019: Predictors of sustained functional cure in HBeAg-negative patients achieving HBsAg seroclearance with interferon-alfa-based therapy[J]. J Viral Hepat, 26, 32-41.
-
Liu J, Yang HI, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, You SL, Chen CJ, 2016: Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression[J]. Hepatology, 64, 381-389. doi: 10.1002/hep.28552
-
Mak LY, Seto WK, Fung J, Yuen MF, 2019: Novel developments of hepatitis B: treatment goals, agents and monitoring tools[J]. Expert Rev Clin Pharmacol, 12, 109-120. doi: 10.1080/17512433.2019.1567327
-
Manesis EK, Papatheodoridis GV, Hadziyannis E, 2010: significance of serum HBsAg levels for the definition of the inactive hepatitis B carrier state[J]. Hepatology, 52, 560A-.
-
Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M, 2014: Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)[J]. J Hepatol, 61, 777-784. doi: 10.1016/j.jhep.2014.05.044
-
Papatheodoridis GV, 2011: Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues[J]. Liver Int, 31, 95-103. doi: 10.1111/j.1478-3231.2010.02392.x
-
Marcellin, Lau, Bonino, Farci, Hadziyannis, Jin, Lu, Piratvisuth, Germanidis, Yurdaydin, Diago, Gurel, Lai, Button, Pluck, Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group, 2004: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B[J]. N Engl J Med, 351, 1206-1217. doi: 10.1056/NEJMoa040431
-
Marcellin, Bonino, Lau, Farci, Yurdaydin, Piratvisuth, Jin, Gurel, Lu, Wu, Popescu, Hadziyannis, Peginterferon alfa-2a in HBeAgnegative Chronic Hepatitis B Study Group, 2009: Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a[J]. Gastroenterology, 136, 2169-2179. doi: 10.1053/j.gastro.2009.03.006
-
Patrick M, Lau George KK, Ferruccio B, Patrizia F, Stephanos H, Jin Rui L, Zhi-Meng PT, Georgios G, Cihan Y, Moises D, Selim G, Ming-Yang L, Peter B, Nigel P, 2004: Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group[J]. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 351, 1206-1217.
-
Patrick, Ferruccio, Lau George, Patrizia, Cihan, Teerha, Rui, Gurel, Jian, Matei, Stephanos, Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group, 2009: Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a[J]. Gastroenterology, 136, 2169-2179. doi: 10.1053/j.gastro.2009.03.006
-
Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Raptopoulou-Gigi M, Ormeci N, Zondervan PE, Verhey E, van Vuuren AJ, Hansen BE, Janssen HL, PARC Study Group (2010) A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 105: 1762–1769
-
Seto WK, Lo YR, Pawlotsky JM, Yuen MF, 2018: Chronic hepatitis B virus infection[J]. Lancet, 392, 2313-2324. doi: 10.1016/S0140-6736(18)31865-8
-
Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, Williams J, 2010: Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus[J]. Hepatology, 51, 1531-1537. doi: 10.1002/hep.23464
-
Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL, 2013: Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels[J]. Hepatology, 58, 872e80-. doi: 10.1002/hep.26436
-
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB, 2018: Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 67, 1560-1599. doi: 10.1002/hep.29800
-
WHO. Global hepatitis report 2017. Geneva. https://www.who.int/hepatitis/publications/global-hepatitisreport2017/en/. Accessed 4 April 2019
-
Xie Y, Yi W, Zhang L, Lu Y, Hao HX, Gao YJ, Ran CP, Lu HH, Chen QQ, Shen G, Wu SL, Chang M, Hu LP, Liu RY, Sun L, Wan G, Li MH, 2019: Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigen-negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels[J]. J Viral Hepat, 26, 42-49.
-
Yim HJ, Lok AS, 2006: Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005[J]. Hepatology, 43, S173-S181. doi: 10.1002/hep.20956